#United States #San Diego #Singular Genomics #John Stark #G4X Platform

Singular Genomics Appoints John Stark as CEO

On April 28, 2026, Singular Genomics Systems, Inc. officially announced that John Stark will take over as Chief Executive Officer. This strategic move is set against the backdrop of the company's ongoing progress with its spatial platform, particularly following the recent successful launch of the G4X platform. In light of this transition, Josh Stahl will now serve as an Independent Director on the Board.

Allison Ballmer, Chair of the Board, expressed optimism regarding this leadership change, stating, "With Singular's G4X platform now successfully on the market, the company is positioned to realize spatial pathology's potential across translational research and clinical applications." She highlighted the transformation that Josh led at Singular, which culminated in the successful introduction of the G4X platform. Now, with John's extensive leadership experience in innovative technology commercialization, the company aims to scale its operations and harness the growing demand for precision medicine.

John Stark joins Singular Genomics with over 25 years of expertise in driving technological advancements and fostering business growth. Before this, he served as CEO of Resolve Biosciences, a company specializing in spatial biology, where he played a significant role in forging partnerships and integrating solutions in various research fields, including drug development and clinical research. Prior to that, he held CEO positions at Quantum-Si and Celsee, focusing on next-generation sequencing technologies and single-cell genomics, respectively.

In a statement, Stark remarked, "Singular has built a competitive spatial platform and a strong foundation in a rapidly evolving market. I am excited to build on that momentum by deepening partnerships, scaling adoption, and unlocking broader value from spatial data across research, drug development, and precision medicine."

Andrew ElBardissi from Deerfield Management emphasized the pivotal contributions of Josh Stahl in laying a strong foundation for Singular, while welcoming John Stark to the team, who is expected to bring his wealth of experience to propel its growth trajectory. He stated, "We remain confident in Singular's technology, market opportunity, and path to leadership in precision medicine and are committed to supporting the company's continued growth."

About Singular Genomics

Singular Genomics is a pioneering life science technology enterprise focused on delivering advanced spatial pathology solutions aimed at enhancing precision medicine efforts. The company’s G4X™ Spatial Sequencer stands out for its capacity to enable scalable, multiomic analyses directly within tissues. This innovative approach merges high performance, elevated throughput, and cost-effectiveness, providing essential support for translational research, artificial intelligence-driven insights, and clinical progression. Headquartered in San Diego, California, Singular continues to push the boundaries of what is possible in genomic research and application.

Forward-Looking Statements

Readers should be mindful that some statements in this announcement may be forward-looking and involve inherent risks and uncertainties that could result in actual outcomes differing materially from the projected expectations. Singular Genomics commits to no obligation for updating these forward-looking statements unless mandated by law.